Metabolites of procainamide and practolol inhibit complement components C3 and C4

Area of Science:

• Pharmacology
• Immunology
• Toxicology

Background:

• Drug-induced systemic lupus erythematosus (DILE) is a serious adverse effect linked to several medications.
• Hydralazine and isoniazid are known to inhibit complement C3 and C4 covalent binding, potentially causing immune complex deposition.
• The mechanism by which procainamide and practolol induce DILE is less understood, as these drugs themselves do not inhibit C3 and C4.

Purpose of the Study:

• To investigate the potential role of metabolites in procainamide- and practolol-induced systemic lupus erythematosus.
• To determine if synthesized metabolites of procainamide and practolol can inhibit complement C3 and C4 covalent binding.
• To highlight the importance of measuring hydroxylamine metabolites in human tissues for understanding DILE.

Main Methods:

• Synthesis of various metabolites and putative metabolites of procainamide and practolol.
• Testing the inhibitory effects of these synthesized compounds on the covalent binding reactions of complement components C3 and C4.
• Comparing the inhibitory potential of drug metabolites to that of the parent drugs.

Main Results:

• The hydroxylamine metabolite of procainamide demonstrated strong inhibition of C3 and C4 covalent binding.
• A putative hydroxylamine metabolite of practolol also exhibited significant inhibitory activity against C3 and C4 covalent binding.
• Parent drugs procainamide and practolol did not inhibit C3 and C4 covalent binding, unlike their hydroxylamine metabolites.

Conclusions:

• Hydroxylamine metabolites of procainamide and practolol are likely mediators of the toxic side effects leading to drug-induced systemic lupus erythematosus.
• The findings underscore the critical need for quantifying hydroxylamine metabolite levels in human tissues to better understand and potentially prevent DILE.
• Further research into the specific mechanisms of hydroxylamine metabolite toxicity is warranted.